Dendritic cell vaccine - Shanghai Cell Therapy Group
Alternative Names: Super DC VaccineLatest Information Update: 28 Sep 2026
At a glance
- Originator Shanghai Cell Therapy Group
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 28 Sep 2026 No recent reports of development identified for phase-I development in Solid-tumours(Adjuvant therapy) in China (Parenteral, Injection)
- 31 Jul 2025 Phase-I/II clinical trials in Solid tumours (Prevention) in China (Parenteral) (NCT07146672)
- 31 Aug 2023 Phase-I clinical trials in Solid tumours (Adjuvant therapy) in China (Parenteral) (NCT06015269)